Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNIPR-EED
- Development stage
- Preclinical
- Lead developer
- SNIPR Biome
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
SNIPR-EED is a preclinical CRISPR-based precision antimicrobial therapy being developed by SNIPR Biome. It is designed to selectively target and kill specific pathogenic bacteria, namely *Escherichia coli* and *Klebsiella pneumoniae*, in the gut. The primary indication for SNIPR-EED is Environmental Enteric Dysfunction (EED), a condition characterized by chronic gut inflammation and reduced nutrient absorption common in low- and middle-income countries. The technology utilizes CRISPR-Cas armed bacteriophages (viruses that infect bacteria) to precisely eliminate the target bacteria without harming the beneficial components of the gut microbiome. SNIPR Biome is developing this therapy with support from a grant from the Bill & Melinda Gates Foundation, particularly focusing on improving EED in pregnant women to prevent negative impacts on fetal development. [1]
Beyond the preview
Go deeper on SNIPR-EED.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNIPR-EED.